Understanding NSAID-Induced Skin Reactions: Implications for Patient Care
##plugins.themes.bootstrap3.article.main##
Abstract
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed medications used to alleviate pain, inflammation, and fever. However, their widespread use is often accompanied by the risk of adverse drug reactions, including cutaneous hypersensitivity reactions. This research aims to investigate the epidemiology, underlying mechanisms, and implications for patient management in individuals experiencing NSAID-induced skin reactions. Through a comprehensive review of literature and analysis of clinical data, this study provides insights into the incidence, clinical characteristics, and risk factors associated with NSAID-induced skin reactions. Findings reveal a spectrum of adverse events, ranging from mild erythematous rashes to severe cutaneous adverse reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Risk factors including advanced age, female gender, atopy, genetic polymorphisms, and NSAID class are identified, highlighting the importance of personalized risk assessment in clinical practice. Potential mechanisms underlying NSAID-induced skin reactions are elucidated, encompassing dysregulation of cyclooxygenase enzymes, altered production of pro-inflammatory mediators, immunological dysregulation, genetic predisposition, and oxidative stress. Understanding these mechanisms is critical for guiding targeted therapeutic interventions and optimizing patient care. Implications of study findings for clinical practice and patient management are discussed, emphasizing the need for individualized treatment regimens, patient education, multidisciplinary collaboration, and pharmacovigilance.
##plugins.themes.bootstrap3.article.details##
Actor, J. K., & Smith, K. C. (2019). Translational inflammation. In Translational Inflammation (pp. 1–22). Elsevier.
Atchison, J. W., Herndon, C. M., & Rusie, E. (2013). NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. Journal of Managed Care Pharmacy, 19(9 Supp A), 1–19.
Balakirski, G., & Merk, H. F. (2017). Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutaneous and Ocular Toxicology, 36(4), 307–316.
Baldo, B. A., & Pham, N. H. (2020). Drug allergy: clinical aspects, diagnosis, mechanisms, structure-activity relationships.
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020). Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochemical Pharmacology, 180, 114147.
Blanca-Lopez, N., Soriano, V., Garcia-Martin, E., Canto, G., & Blanca, M. (2019). NSAID-induced reactions: classification, prevalence, impact, and management strategies. Journal of Asthma and Allergy, 217–233.
Chen, C.-B., Abe, R., Pan, R.-Y., Wang, C.-W., Hung, S.-I., Tsai, Y.-G., & Chung, W.-H. (2018). An updated review of the molecular mechanisms in drug hypersensitivity. Journal of Immunology Research, 2018.
Ferraz, C. R., Carvalho, T. T., Manchope, M. F., Artero, N. A., Rasquel-Oliveira, F. S., Fattori, V., Casagrande, R., & Verri Jr, W. A. (2020). Therapeutic potential of flavonoids in pain and inflammation: mechanisms of action, pre-clinical and clinical data, and pharmaceutical development. Molecules, 25(3), 762.
Fokunang, C., Fokunang, E. T., Frederick, K., Ngameni, B., & Ngadjui, B. (2018). Overview of non-steroidal anti-inflammatory drugs (nsaids) in resource limited countries. Moj Toxicol, 4(1), 5–13.
Fragkas, N. (2020). Immunological investigations into naproxen-induced idiosyncratic hepatotoxicity. University_of_Basel.
Ganter, B., Snyder, R. D., Halbert, D. N., & Lee, M. D. (2006). Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix® database.
Gomes, E. R., & Kuyucu, S. (2017). Epidemiology and risk factors in drug hypersensitivity reactions. Current Treatment Options in Allergy, 4, 239–257.
Gunter, N. V., Yap, B. J. M., Chua, C. L. L., & Yap, W. H. (2019). Combining understanding of immunological mechanisms and genetic variants toward development of personalized medicine for psoriasis patients. Frontiers in Genetics, 10, 440505.
Marzano, A. V, Borghi, A., & Cugno, M. (2016). Adverse drug reactions and organ damage: the skin. European Journal of Internal Medicine, 28, 17–24.
Mody, H., Ramakrishnan, V., Chaar, M., Lezeau, J., Rump, A., Taha, K., Lesko, L., & Ait‐Oudhia, S. (2020). A review on drug‐induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. Clinical Pharmacology in Drug Development, 9(8), 896–909.
Osborne, P., & Buehl, O. B. (2016). No Grain, No Pain: a 30-day diet for eliminating the root cause of chronic pain. Simon and Schuster.
Panel, N.-S. E. (2010). Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. Journal of Allergy and Clinical Immunology, 126(6), S1–S58.
Paulmann, M., & Mockenhaupt, M. (2019). Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo Journal International, 28, 311–326.
Pichler, W. J., & Hausmann, O. (2017). Classification of drug hypersensitivity into allergic, pi, and pseudo-allergic forms. International Archives of Allergy and Immunology, 171(3–4), 166–179.
Pillans, P. I. (2008). Clinical perspectives in drug safety and adverse drug reactions. Expert Review of Clinical Pharmacology, 1(5), 695–705.
Quaresma, J. A. S. (2019). Organization of the skin immune system and compartmentalized immune responses in infectious diseases. Clinical Microbiology Reviews, 32(4), 10–1128.
Sánchez-Borges, M., Capriles-Hulett, A., & Caballero-Fonseca, F. (2005). Risk of skin reactions when using ibuprofen-based medicines. Expert Opinion on Drug Safety, 4(5), 837–848.
Sanghera, R., & Grewal, P. S. (2019). Dermatological symptom assessment. Patient Assessment in Clinical Pharmacy: A Comprehensive Guide, 133–154.
Schmitt, M. R., Miller, M. J., Harrison, D. L., Farmer, K. C., Allison, J. J., Cobaugh, D. J., & Saag, K. G. (2011). Communicating non-steroidal anti-inflammatory drug risks: verbal counseling, written medicine information, and patients’ risk awareness. Patient Education and Counseling, 83(3), 391–397.
van Hoof, J. J., Cents, M. H. G., Megens, N. M. J., & van der Tang, S. J. (2014). Druggists and pharmacists as gatekeepers: sales routines and compliance with sales protocols for over-the-counter naproxen 275 mg medicines in the Netherlands. Health Policy, 117(3), 353–360.
Wallace, J. L., & Soldato, P. Del. (2003). The therapeutic potential of NO‐NSAIDs. Fundamental & Clinical Pharmacology, 17(1), 11–20.
Wöhrl, S. (2018). NSAID hypersensitivity–recommendations for diagnostic work up and patient management. Allergo Journal International, 27, 114–121.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.